Viable newcastle disease vaccine strains in a pharmaceutical dump by A. Amendola et al.
Viable Newcastle 
Disease Vaccine 
Strains in a 
Pharmaceutical 
Dump
Antonella Amendola,* Silvia Bianchi,* 
Marta Canuti,* Alessandra Zappa,* 
Giovanna Zanoni,† Raffaella Koncan,† 
Elisabetta Tanzi,* Giuseppe Cornaglia,† 
Alessandro Remo Zanetti,* 
and Giuseppe Tridente†
To assess the viability of discarded and buried vaccine 
strains, we examined vaccines that had been buried for >20 
years in an industrial waste dump in the city of Milan, Italy. 
Viability results showed potential biological risk associated 
with uncontrolled burial of pharmaceutical industry waste, 
including some live vaccines.
During most of the 20th century, biopharmacologic prod-ucts, including vaccines, prophylactic serum, blood 
fl asks, and animal-origin waste, were buried <1.5 m deep 
in the 12,000-m2 waste dump of a pharmaceutical research 
institute in Milan (Istituto Sieroterapico Milanese [ISM]). 
ISM was founded in 1886 but bankrupt by 1994. This 
dump area was recently reclaimed after nearly a decade of 
abandonment.
Some of the material with potential biological risk, 
such as animal carcasses, has been decomposing in di-
rect contact with the soil. Other material, including vac-
cines against human and animal diseases such as rabies, 
poliomyelitis, anthrax, and Newcastle disease (ND), were 
recovered in hermetically sealed vials, so their contents 
might have been totally or partially preserved. Our aim in 
this preliminary study was to assess the viability of the un-
earthed vaccines. 
The Study
The reclamation procedure was performed under strict 
safety conditions. All operations were conducted under 
biocontainment tents that had air exchangers and extractors 
with fi lters. Full personal protective equipment, including 
biohazard suits, gas masks, and gauntlets, was provided to 
all workers. The amount of biopharmacologic waste re-
moved was impressive (35,764 tons). In particular, large 
quantities of ND vaccines were recovered, in liquid and in 
lyophilized form; the estimated net weight of biological 
material was 20–25 kg.
Four vaccine types against ND (2 in liquid and 2 in 
lyophilized form) were unearthed from the dump. A review 
of documentation found that all 4 types had been produced 
by ISM from 1975 through 1988. Because the exact com-
position of the vaccines was unknown, the vial contents 
were subjected to viability tests in culture and to molecular 
characterization assays. The viability evaluations were per-
formed by inoculation of the vial contents onto a confl uent 
monolayer of Vero cells (African green monkey kidney), 
followed by observation of the cell culture for 7 days and 
assessment of any cytopathic effect (1). Each assay was 
performed twice. The positive control was a commercially 
available ND vaccine (Izovac; IZO S.p.A, Brescia, Italy), 
containing >106 50% embryo infectious dose live attenu-
ated viruses.
As a result of bacterial contamination, no virus could be 
isolated from the 2 types of liquid vaccine. However, virus 
was isolated from the 2 lyophilized ND vaccine strains and 
caused cytopathic effect, which was further confi rmed by 
hemoadsorbing assay (Figure 1). These lyophilized strains, 
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Figure 1. A) Cytopathic effect of lyophilized Newcastle disease 
virus (NDV) vaccine strains on Vero cells. B) Hemagglutination test. 
Presence of tear-shaped erythrocytes confi rms the specifi city of the 
cytopathic effect of NDV on Vero cells.
DISPATCHES
which showed vitality in Vero cells, were then propagated 
in embryonated chicken eggs, the preferred substrate for 
ND virus (NDV) growth. Briefl y, samples were inoculated 
into the allantoic cavity of 10-day-old embryonated chick-
en eggs and further incubated at 36°C for 5 days. Eggs 
were subsequently chilled to 4°C, and the allantoic fl uid 
was tested for hemagglutination (HA) activity to confi rm 
the presence of viral replicaion (2). A 512-fold increase of 
HA titer was observed after infection (i.e., from 4 HA units 
in the whole, resuspended vaccine to 2.048 HA units in the 
allantoic fl uid). 
An additional part of the original vial content of the un-
earthed vaccines was used for molecular characterization. 
Viral RNA extracted from all 4 vaccine types (liquid and 
lyophilized) was subjected to sequencing of the genomic 
region, including the cleavage site, which is the determi-
nant of virulence for NDV strains (3,4). For this purpose, 
vial content was subjected to genic amplifi cation of a 615-
bp fragment (5) of the F gene, which encodes for the fusion 
protein. The nucleotide sequence obtained was aligned with 
sequences in online databases by using ClustalX software 
(ftp://ftp.ebi.ac.uk/pub/software/unix/clustalx). The amino 
acid sequence was then predicted with BioEdit software 
(www.mbio.ncsu.edu/bioedit/bioedit.html), and a detailed 
analysis was performed on the cleavage site (Table). The 
phylogenetic tree of the F gene fragment (Figure 2) provid-
ed the vaccine strain’s classifi cation. The lyophilized sam-
ples contained La Sota–like strains classifi ed as lentogenic 
strains. The liquid samples contained genomic sequences 
of the cleavage site characteristic of Herts/33-like strains 
(velogenic strains).
Conclusions
Vast areas that were once used as uncontrolled dumps 
for pharmaceutical industry waste still exist in many coun-
tries. One example is the waste dump of the ISM, which 
was 1 of the leading Italian companies in the fi eld of re-
search and development of vaccines against the infectious 
diseases most prevalent at the time, including diphtheria, 
smallpox, tetanus, anthrax, rabies, and poliomyelitis.
Because of this unusual line of production, the recla-
mation activities of the ISM area took into consideration 
the potential biological risks caused by the buried and un-
processed waste. This fi rst attempt in Italy to reclaim such 
an area yielded large quantities of biological material, in-
cluding well-preserved vaccines and by-products of their 
manufacturing processes. Because data about the manufac-
turing and disposal procedures used at the time are missing, 
the recovery of such biological materials raises concerns 
about persistent biological activity. Moreover, veterinary 
vaccines, especially those in lyophilized form, may repre-
sent a relevant biological risk because they are often pre-
pared with strains that have been attenuated for the target 
animals but not for humans.
This preliminary study considered the residual patho-
genic potential of ND vaccines. ND is a viral infection of 
poultry, caused by an avian paramyxovirus serotype 1 (6), 
which may cause human disease and may pose a hazard to 
exposed workers (7,8). ND infections usually cause unilat-
eral or bilateral reddening and edema of the eyelids, exces-
sive lacrimation, conjunctivitis, and subconjunctival hem-
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Figure 2. Phylogenetic analysis of Newcastle disease virus (NDV) 
vaccine strains unearthed from Istituto Sieroterapico Milanese 
(ISM), showing the phylogenetic placement of ISM-1 (EU082818), 
ISM-2 (EU082819), ISM-3 (EU082820), and ISM-4 (EU082818) 
based on partial F gene necleotide sequences. Sequences 
determined in this study are in boldface. ISM-1 and ISM-2 belong 
to La Sota–like cluster; ISM-3 and ISM-4 belong to Herts/33-like 
cluster. Sequence alignment was achieved with ClustalX version 
1.81 (ftp://ftp.ebi.ac.uk/pub/software/unix/clustalx), with sequences 
from other NDV strains retrieved from GenBank (accession nos. 
indicated). The phylogenetic study was conducted by using MEGA 
version 3.1 (www.megasoftware.net). The phylogenetic tree was 
constructed with the neighbor-joining method.
Table. Comparison of Newcastle disease virus sequences  
Classification* Amino acid sequence
 Lentogenic 112(G/E)(R/K)Q(G/E)RL117
 Velogenic 112(R/K)RQ(R/K)RF117
Strains† Nucleotide/amino acid sequence
 ISM-1, ISM-2 GGG AGA CAG GGG CGC CTT 
112G R Q G R L117
 ISM-3, ISM-4 AGG AGA CAG AGA CGG TTT 
112R R Q R R F117
*Amino acid sequences at the F protein cleavage site of lentogenic and 
velogenic strains of Newcastle disease virus.  
†Nucleotide/amino acid sequences of the samples recovered from a dump 
at Istituto Sieroterapico Milanese (ISM), Milan, Italy, and analyzed in this 
study. ISM-1 and ISM-2 (GenBank accession nos. EU082818 and 
EU082819, respectively) were recovered in lyophilized form; ISM-3 and 
ISM-4 (GenBank accession nos. EU082820 and EU082821, respectively) 
were recovered in liquid form. The cleavage site sequences of ISM-1 and 
ISM-2 are typical of lentogenic strains; the cleavage site sequences of 
ISM-3 and ISM-4 are typical of velogenic strains. 
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orrhage. ND infections are usually transient with no corneal 
involvement (9); however, severe complications leading to 
lasting vision impairment have been described (10).
The viability data of lyophilized strains of live NDV 
vaccines, conserved in hermetically sealed vials and buried 
for >20 years, showed that the strains had persisting rep-
lication ability in Vero cells and in embryonated chicken 
eggs. This residual vitality implies that manipulation of 
discarded vaccines may involve risk for infection. Molecu-
lar characterization of the F gene classifi ed the lyophilized 
vaccines as derived from lentogenic strains. On the con-
trary, the cleavage site of the liquid vaccines contained ge-
nomic sequences characteristic of velogenic strains. That 
the liquid vaccine originally consisted of inactivated NDV 
or of velogenic strains (used in the past) attenuated by sev-
eral passages in culture systems is possible.
This study indicates the existence of biological risk de-
riving from the uncontrolled burial of vaccines and their by-
products and underlines the absence of worldwide-accepted 
criteria defi ning the extent and persistence of biological risk–
related biopharmacologic waste materials. The results of the 
study support the need to plan and perform rational reclama-
tion operations in abandoned biopharmaceutical waste areas, 
implementing biocontainment strategies and personal and 
environmental safety measures. These measures are particu-
larly necessary in those situations in which the buried mate-
rial could contain highly infectious and pathogenic agents 
such as pox and anthrax, which were largely used by leading 
vaccine producers in the past century.
In conclusion, further studies are needed to fi ll 
knowledge gaps regarding disposed biological material. 
Such studies are warranted to evaluate the extent and the 
persistence of the infectious risk brought about by buried 
vaccines.
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